Jack A Roth

List of Publications by Year
in descending order

195 papers	11,649 citations	47 h-index 47006	101 g-index 31849
246 all docs	246 docs citations	246 times ranked	15016 citing authors

#	Article	IF	Citations
1	Robotic Surgery and Anatomic Segmentectomy: An Analysis of Trends, Patient Selection, and Outcomes. Annals of Thoracic Surgery, 2022, 113, 975-983.	1.3	12
2	Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2022, 113, 200-208.	1.3	16
3	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer, 2022, 164, 69-75.	2.0	2
4	Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1327-1337.	0.8	29
5	Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific Reports, 2022, 12, 1248.	3.3	3
6	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
7	TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model. Communications Biology, 2022, 5, 167.	4.4	5
8	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	12.8	23
9	Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Annals of Thoracic Surgery, 2022, 114, 2032-2040.	1.3	8
10	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	3.1	7
11	The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era. Journal of Surgical Research, 2022, 277, 125-130.	1.6	1
12	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Network Open, 2022, 5, e2215589.	5.9	15
13	Molecular parameters impacting the success rate of a lung cancer PDX model.. Journal of Clinical Oncology, 2022, 40, e20592-e20592.	1.6	0
14	Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 1404-1412.e2.	0.8	14
15	Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Annals of Thoracic Surgery, 2021, 111, 1133-1140.	1.3	5
16	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest, 2021, 159, 1256-1264.	0.8	14
17	Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac. Annals of Thoracic Surgery, 2021, 111, 1111-1117.	1.3	0
18	Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. European Journal of Cardio-thoracic Surgery, 2021, 59, 100-108.	1.4	23

#	Article	IF	Citations
19	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118
20	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
21	Intestinal Metaplasia in the Esophageal Remnant Is Rare After Ivor Lewis Esophagectomy. Journal of Gastrointestinal Surgery, 2021, 25, 2185-2191.	1.7	3
22	Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature, 2021, 590, 504-508.	27.8	79
23	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39, 346-360.e7.	16.8	422
24	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62
25	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 601-609.	1.1	40
26	Pulmonary resection for tissue harvest in adoptive tumorâ€infiltrating lymphocyte therapy: Safety and feasibility. Journal of Surgical Oncology, 2021, 124, 699-703.	1.7	2
27	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma.. Journal of Clinical Oncology, 2021, 39, 4067-4067.	1.6	1
28	Preoperative Maximum Standardized Uptake Value Associated with Recurrence Risk In Early Lung Cancer. Annals of Thoracic Surgery, 2021, , .	1.3	7
29	Modern Perioperative Practices May Mitigate Effects of Continued Smoking Among Lung Cancer Patients. Annals of Thoracic Surgery, 2021, , .	1.3	0
30	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
31	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	12.8	58
32	Liposomal Bupivacaine Intercostal Block Is Important for Reduction of Pulmonary Complications. Annals of Thoracic Surgery, 2021, 112, 423-429.	1.3	9
33	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncology, The, 2021, 22, 1448-1457.	10.7	154
34	Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. Annals of Surgery, 2021, 274, 1099-1106.	4.2	22
35	STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clinical Cancer Research, 2021, 27, 1720-1733.	7.0	44
36	SABR for operable stage I non-small-cell lung cancer: comparison to surgery â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e537-e538.	10.7	0

#	Article	IF	Citations
37	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	7.0	80
38	Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. Annals of Thoracic Surgery, 2020, 109, 404-411.	1.3	8
39	Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene, 2020, 39, 801-813.	5.9	16
40	From clinical specimens to human cancer preclinical modelsâ€"a journey the NCIâ€cell line databaseâ€"25 years later. Journal of Cellular Biochemistry, 2020, 121, 3986-3999.	2.6	6
41	Surveillance After Treatment of Non-Small-Cell Lung Cancer: A Call for Multidisciplinary Standardization. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2020, 15, 57-65.	0.9	3
42	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer, 2020, 149, 33-40.	2.0	12
43	Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer. , 2020, 8, e000336.		9
44	Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms. Journal of Surgical Oncology, 2020, 122, 515-522.	1.7	3
45	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer, 2020, 146, 303-309.	2.0	2
46	Hospital readmissions after pulmonary resection: post-discharge nursing telephone assessment identifies high risk patients. Journal of Thoracic Disease, 2020, 12, 184-190.	1.4	5
47	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. Journal of Surgical Oncology, 2020, 121, 984-989.	1.7	1
48	Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Nonâ€"Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clinical Lung Cancer, 2020, 21, e294-e301.	2.6	10
49	Time trends and predictors of survival in surgically resected earlyâ€stage nonâ€"small cell lung cancer patients. Journal of Surgical Oncology, 2020, 122, 495-505.	1.7	10
50	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clinical Lung Cancer, 2020, 21, 341-348.	2.6	70
51	Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. Journal of Thoracic Disease, 2020, 12, 329-337.	1.4	4
52	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Annals of Thoracic Surgery, 2020, 110, 1131-1138.	1.3	8
53	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	1.1	109
54	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020, 1, 423-436.	13.2	218

#	Article	IF	Citations
55	Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding. Seminars in Thoracic and Cardiovascular Surgery, 2020, 32, 337-343.	0.6	6
56	KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. American Journal of Cancer Research, 2020, 10, 4464-4475.	1.4	5
57	Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Annals of Thoracic Surgery, 2019, 108, 845-851.	1.3	14
58	Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience. Annals of Thoracic Surgery, 2019, 108, 370-376.	1.3	58
59	Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 911-919.e6.	0.8	21
60	Tumor characteristics associated with engraftment of patientâ€derived nonâ€“small cell lung cancer xenografts in immunocompromised mice. Cancer, 2019, 125, 3738-3748.	4.1	31
61	Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. Journal of Surgical Oncology, 2019, 120, 729-735.	1.7	20
62	Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component. Journal of Thoracic Disease, 2019, 11, 3391-3398.	1.4	6
63	Ground Glass Lesions on Chest Imaging: Evaluation of Reported Incidence in Cancer Patients Using Natural Language Processing. Annals of Thoracic Surgery, 2019, 107, 936-940.	1.3	15
64	An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunology Research, 2019, 7, 1267-1279.	3.4	92
65	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1021-1031.	1.1	79
66	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Research, 2019, 79, 125-132.	0.9	56
67	A 5-microRNA signature identified from serum microRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer. Carcinogenesis, 2019, 40, 643-650.	2.8	52
68	Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1648-1655.	0.8	33
69	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. Clinical Cancer Research, 2019, 25, 150-157.	7.0	13
70	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Nonâ€“small-cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2019, 20, 43-47.	2.6	45
71	Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9017-9017.	1.6	9
72	Glutathione reductase () gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. American Journal of Cancer Research, 2019, 9, 1201-1211.	1.4	1

#	Article	IF	Citations
73	Predictors of trimodality therapy and trends in therapy for malignant pleural mesotheliomaâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 960-966.	1.4	19
74	Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2635-2645.e15.	0.8	5
75	Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. Annals of Thoracic Surgery, 2018, 105, 1671-1677.	1.3	19
76	Comparison of outcomes between muscle-sparing thoracotomy and video-assisted thoracic surgery in patients with cT1 N0 M0 lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1307.	0.8	0
77	Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Medicine, 2018, 7, 2405-2414.	2.8	22
78	TUSC2 Immunogene Therapy Synergizes with Antiâ€“PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models. Cancer Immunology Research, 2018, 6, 163-177.	3.4	30
79	Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components. Annals of Thoracic Surgery, 2018, 106, 235-241.	1.3	12
80	Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer. Annals of Thoracic Surgery, 2018, 106, 272-279.	1.3	153
81	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. OncoImmunology, 2018, 7, e1376156.	4.6	14
82	Serum MicroRNAâ€150 Predicts Prognosis for Earlyâ€Stage Nonâ€Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clinical Pharmacology and Therapeutics, 2018, 103, 1061-1073.	4.7	31
83	Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cellâ€free DNA by nextâ€generation sequencing. Cancer, 2018, 124, 1061-1069.	4.1	11
84	Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. British Journal of Cancer, 2018, 118, 331-337.	6.4	10
85	Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Targeted Oncology, 2018, 13, 99-106.	3.6	10
86	Occult stage IIIA-N2 patients have excellent overall survival with initial surgery. Journal of Thoracic Disease, 2018, 10, 6670-6676.	1.4	12
87	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. Journal of Translational Medicine, 2018, 16, 328.	4.4	12
88	Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women. Annals of Thoracic Surgery, 2018, 106, 1499-1503.	1.3	6
89	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research, 2018, 24, 6195-6203.	7.0	292
90	Predictors of survival after resection of primary sarcomas of the chest wallâ€”A large, singleâ€institution series. Journal of Surgical Oncology, 2018, 118, 518-524.	1.7	20

#	Article	IF	Citations
91	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunology Research, 2017, 5, 319-329.	3.4	25
92	Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy. Carcinogenesis, 2017, 38, 419-424.	2.8	10
93	Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction?. Annals of Thoracic Surgery, 2017, 103, 1710-1714.	1.3	8
94	7â€year followâ€up after stereotactic ablative radiotherapy for patients with stage I nonâ€“small cell lung cancer: Results of a phase 2 clinical trial. Cancer, 2017, 123, 3031-3039.	4.1	125
95	Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. Annals of Thoracic Surgery, 2017, 104, 1821-1828.	1.3	7
96	Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy. Lung Cancer, 2017, 114, 70-78.	2.0	15
97	Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics. Oncotarget, 2017, 8, 48222-48239.	1.8	9
98	Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities. Oncotarget, 2017, 8, 102150-102160.	1.8	3
99	TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC). Oncotarget, 2017, 8, 107621-107629.	1.8	19
100	Gene Therapy for Lung Cancer. Critical Reviews in Oncogenesis, 2016, 21, 115-124.	0.4	21
101	MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Nonâ€“Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0150467.	2.5	7
102	MicroRNA-mediated target mRNA cleavage and 3â€²-uridylation in human cells. Scientific Reports, 2016, 6, 30242.	3.3	26
103	Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Annals of Thoracic Surgery, 2016, 101, 1075-1081.	1.3	18
104	Glycemic Index, Glycemic Load, and Lung Cancer Risk in Non-Hispanic Whites. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 532-539.	2.5	33
105	Detection of siRNA-mediated target mRNA cleavage activities in human cells by a novel stem-loop array RT-PCR analysis. Biochemistry and Biophysics Reports, 2016, 6, 16-23.	1.3	8
106	The Influence of Reconstructive Technique on Perioperative Pulmonary and Infectious Outcomes Following Chest Wall Resection. Annals of Thoracic Surgery, 2016, 102, 1653-1659.	1.3	34
107	TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Scientific Reports, 2016, 6, 35741.	3.3	22
108	Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S.. Scientific Reports, 2016, 6, 26760.	3.3	18

#	Article	IF	Citations
109	Results of Postdischarge Nursing Telephone Assessments: Persistent Symptoms Common Among Pulmonary Resection Patients. Annals of Thoracic Surgery, 2016, 102, 276-281.	1.3	19
110	Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2016, 17, e42-e43.	10.7	2
111	MicroRNA-124 Suppresses Tumor Cell Proliferation and Invasion by Targeting CD164 Signaling Pathway in Non-Small Cell Lung Cancer. Journal of Gene Therapy, 2016, 2, .	1.0	22
112	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget, 2016, 7, 3548-3558.	1.8	114
113	Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients. Scientific Reports, 2015, 5, 12068.	3.3	11
114	Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PLoS ONE, 2015, 10, e0123967.	2.5	27
115	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Letters, 2015, 357, 179-185.	7.2	81
116	Limitations of 18F-2-Deoxy-d-Glucose Positron Emission Tomography in N1 Detection in Patients With Pathologic Stage II-N1 and Implications for Management. Annals of Thoracic Surgery, 2015, 99, 414-420.	1.3	9
117	Surgery versus SABR for resectable non-small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e374-e375.	10.7	10
118	Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncology, The, 2015, 16, 630-637.	10.7	1,220
119	Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. Oncotarget, 2015, 6, 345-354.	1.8	10
120	RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget, 2015, 6, 11114-11124.	1.8	7
121	Genetic variants of the Wnt signaling pathway as predictors of recurrence and survival in early-stage non-small cell lung cancer patients. Carcinogenesis, 2014, 35, 1284-1291.	2.8	19
122	Thoracoscopic lobectomy is associated with improved short-term and equivalent oncological outcomes compared with open lobectomy for clinical Stage I non-small-cell lung cancer: a propensity-matched analysis of 963 cases. European Journal of Cardio-thoracic Surgery, 2014, 46, 607-613.	1.4	112
123	Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Nonâ€“Small Cell Lung Cancer Cells. Journal of the National Cancer Institute, 2014, 106, .	6.3	88
124	Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380. Bioorganic and Medicinal Chemistry, 2014, 22, 5234-5240.	3.0	8
125	Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer: How to Fly in a â€œNo Fly Zoneâ€• International Journal of Radiation Oncology Biology Physics, 2014, 88, 1120-1128.	0.8	225
126	Inflammation-Related Genetic Variations and Survival in Patients With Advanced Nonâ€“Small Cell Lung Cancer Receiving First-Line Chemotherapy. Clinical Pharmacology and Therapeutics, 2014, 96, 360-369.	4.7	16

#	Article	IF	Citations
127	Diaphragmatic Hernia After Esophagectomy in 440 Patients With Long-Term Follow-Up. Annals of Thoracic Surgery, 2013, 96, 1138-1145.	1.3	55
128	Somatostatin Receptor Type 2â€“Based Reporter Expression after Plasmid-Based in Vivo Gene Delivery to Nonâ€“Small Cell Lung Cancer. Molecular Imaging, 2013, 12, 7290.2013.00060.	1.4	4
129	The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner. PLoS ONE, 2013, 8, e77067.	2.5	18
130	Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. Journal of Thoracic Oncology, 2012, 7, 825-832.	1.1	280
131	Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans. PLoS ONE, 2012, 7, e34833.	2.5	149
132	Drug resistance in lung cancer. Lung Cancer: Targets and Therapy, 2010, 1, 23-36.	2.7	59
133	Influence of Age on Choice of Therapy and Surgical Outcomes in Patients with Nonsmall Cell Lung Cancer. American Surgeon, 2009, 75, 598-604.	0.8	7
134	Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Chest, 2009, 136, 701-709.	0.8	105
135	Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455, 1069-1075.	27.8	2,694
136	Gene Therapy in Thoracic Oncology. Annals of Thoracic Surgery, 2008, 85, 1837-1838.	1.3	3
137	Treatment of esophageal cancer: does surgery make the cut?. Gastrointestinal Cancer Research: GCR, 2007, 1, 207-8.	0.7	0
138	Adenovirus p53 gene therapy. Expert Opinion on Biological Therapy, 2006, 6, 55-61.	3.1	117
139	Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Therapy, 2004, 11, 733-739.	4.6	116
140	Gene replacement therapy for nonâ€“small cell lung cancer: a review. Hematology/Oncology Clinics of North America, 2004, 18, 215-229.	2.2	27
141	Tumor Suppressor Gene Therapy. , 2003, 223, 577-598.		13
142	A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer, 2001, 92, 279-286.	4.1	119
143	Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. International Journal of Cancer, 2001, 91, 159-166.	5.1	2
144	Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene, 2001, 20, 5225-5231.	5.9	128

#	Article	IF	Citations
145	Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene, 2001, 20, 6258-6262.	5.9	82
146	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53). Cancer Gene Therapy, 2000, 7, 530-536.	4.6	63
147	Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Therapy, 2000, 7, 537-544.	4.6	36
148	Overexpression of the wild-type p53 gene inhibits NF-ÎºB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene, 2000, 19, 726-736.	5.9	134
149	Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene, 2000, 19, 4432-4436.	5.9	69
150	Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene, 2000, 19, 5359-5366.	5.9	47
151	Gene therapy in lung cancer. Current Oncology Reports, 2000, 2, 64-70.	4.0	13
152	Overexpression of the p21 sdi1 gene induces senescence-like state in human cancer cells: implication for senescence-directed molecular therapy for cancer. Cell Death and Differentiation, 1999, 6, 765-772.	11.2	42
153	Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene, 1999, 18, 2189-2199.	5.9	72
154	Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene, 1998, 16, 1-8.	5.9	70
155	Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene, 1998, 17, 241-246.	5.9	61
156	Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis. Oncogene, 1998, 17, 901-906.	5.9	27
157	Adenovirus-mediated wild-typep53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Annals of Surgical Oncology, 1998, 5, 681-688.	1.5	111
158	Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene, 1997, 14, 379-384.	5.9	131
159	p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene, 1997, 15, 1903-1909.	5.9	84
160	Novel combination therapy for human colon cancer with adenovirus-mediated wild-typep53 gene transfer and DNA-damaging chemotherapeutic agent. , 1997, 73, 367-370.		50
161	Novel combination therapy for human colon cancer with adenovirusâ€mediated wildâ€type p53 gene transfer and DNAâ€damaging chemotherapeutic agent. International Journal of Cancer, 1997, 73, 367-370.	5.1	3
162	Thep53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. Journal of Cancer Research and Clinical Oncology, 1996, 122, 360-365.	2.5	108

#	Article	IF	Citations
163	Analysis of phosphorylated isoforms of the p53 tumor suppressor protein in human lung carcinoma cells undergoing apoptosis. Electrophoresis, 1996, 17, 1772-1775.	2.4	19
164	Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. , 1996, 17, 217-223.		89
165	Modification of Mutant K-ras Gene Expression in Non-Small Cell Lung Cancer (NSCLC). University of Texas M.D. Anderson Cancer Center, Houston, Texas. Human Gene Therapy, 1996, 7, 875-889.	2.7	31
166	Modification of Tumor Suppressor Gene Expression and Induction of Apoptosis in Non-Small Cell Lung Cancer (NSCLC) with an Adenovirus Vector Expressing Wildtype p53 and Cisplatin. University of Texas M.D. Anderson Cancer Center, Houston, Texas. Human Gene Therapy, 1996, 7, 1013-1030.	2.7	50
167	Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer, 1995, 75, 451-456.	4.1	43
168	Loss of Î±1Î²1 and reduced expression of other Î²1 integrins and cam in lung adenocarcinoma compared with pneumocytes. Journal of Surgical Oncology, 1994, 56, 198-208.	1.7	25
169	Retroviral-mediated transduction ofp53 gene increases TGF-Î² expression in a human glioblastoma cell line. International Journal of Cancer, 1994, 56, 834-839.	5.1	27
170	Esophageal cancer: Does preoperative chemotherapy make a difference?. Journal of Surgical Oncology, 1992, 50, 67-69.	1.7	5
171	Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer, 1992, 69, 662-668.	4.1	246
172	Efficacy of pulmonary metastasectomy for recurrent soft tissue sarcoma. Journal of Surgical Oncology, 1991, 47, 1-4.	1.7	46
173	Prognostic indicators in patients with pulmonary metastases. Journal of Surgical Oncology, 1990, 6, 291-296.	1.4	30
174	Lung Cancer Susceptibility and Risk Assessment Models. , 0, , 33-60.		1
175	Molecular Biology of Preneoplastic Lesions of the Lung. , 0, , 84-98.		1
176	Detection of Preneoplastic Lesions. , 0, , 99-110.		2
177	The Molecular Genetics of Lung Cancer. , 0, , 61-83.		24
178	Molecular Profiling for Early Detection and Prediction of Response in Lung Cancer. , 0, , 153-168.		0
179	The Role for Mediastinoscopy in the Staging of Nonsmall Cell Lung Cancer. , 0, , 169-179.		0
180	Minimally Invasive Surgery for Lung Cancer. , 0, , 180-193.		0

#	Article	IF	Citations
181	Extended Resections for Lung Cancer. , 0, , 194-220.		3
182	Adjuvant Chemotherapy Following Surgery for Lung Cancer. , 0, , 221-232.		0
183	Image-Guided Radiation Therapy. , 0, , 247-255.		0
184	Stereotactic Body Radiation Therapy for Lung Cancer. , 0, , 256-270.		1
185	Proton Therapy. , 0, , 271-282.		0
186	Combinations of Radiation Therapy and Chemotherapy for Nonsmall Cell Lung Carcinoma. , 0, , 283-314.		0
187	New Chemotherapeutic Agents in Lung Cancer. , 0, , 315-333.		0
188	Immunologic Approaches to Lung Cancer Therapy. , 0, , 334-351.		0
189	Epidermal Growth Factor Receptor Inhibitors. , 0, , 352-368.		0
190	Proteasome Inhibition in Nonsmall Cell Lung Cancer Therapy. , 0, , 400-410.		0
191	Screening for Early Detection. , 0, , 421-440.		0
192	Natural Agents for Chemoprevention of Lung Cancer. , 0, , 441-455.		0
193	The Pathology and Pathogenesis of Peripheral Lung Adenocarcinoma Including Bronchioloalveolar Carcinoma. , 0, , 121-143.		0
194	Treatment of Bronchioloalveolar Carcinoma. , 0, , 144-152.		0
195	Tumour-Suppressor Gene Therapy. , 0, , 229-239.		0